Abstract
The role of inflammation in the development and progression of cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. The strong dependence of the atherosclerotic process on both a state of continuous low grade inflammation and the presence of lipid abnormalities gave impetus to research the association between hyperlipidemia and inflammatory status. In experimental and clinical studies, several inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, interleukin 6, nuclear factor kappa-β, adhesion molecules, serum amyloid-α, lipoprotein-associated phospholipase A2, fibrinogen and sCD40 ligand are associated with lipids level. Although, cholesterol lowering treatment has several important beneficial effects, there is still little clinical experience or data from clinical trials, in order to treat patients with hyperlipidemia and impaired inflammatory status.
Keywords: Hyperlipidemia, inflammatory markers, cholesterol, lipids, triglycerides, inflammation, atherogenesis, C-Reactive Protein (CRP), TNF-α, nicotinic acid
Current Pharmaceutical Design
Title: Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Volume: 17 Issue: 37
Author(s): Gerasimos Siasos, Dimitris Tousoulis, Evangelos Oikonomou, Marina Zaromitidou, Christodoulos Stefanadis and Athanasios G. Papavassiliou
Affiliation:
Keywords: Hyperlipidemia, inflammatory markers, cholesterol, lipids, triglycerides, inflammation, atherogenesis, C-Reactive Protein (CRP), TNF-α, nicotinic acid
Abstract: The role of inflammation in the development and progression of cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. The strong dependence of the atherosclerotic process on both a state of continuous low grade inflammation and the presence of lipid abnormalities gave impetus to research the association between hyperlipidemia and inflammatory status. In experimental and clinical studies, several inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, interleukin 6, nuclear factor kappa-β, adhesion molecules, serum amyloid-α, lipoprotein-associated phospholipase A2, fibrinogen and sCD40 ligand are associated with lipids level. Although, cholesterol lowering treatment has several important beneficial effects, there is still little clinical experience or data from clinical trials, in order to treat patients with hyperlipidemia and impaired inflammatory status.
Export Options
About this article
Cite this article as:
Siasos Gerasimos, Tousoulis Dimitris, Oikonomou Evangelos, Zaromitidou Marina, Stefanadis Christodoulos and G. Papavassiliou Athanasios, Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice, Current Pharmaceutical Design 2011; 17 (37) . https://dx.doi.org/10.2174/138161211798764780
DOI https://dx.doi.org/10.2174/138161211798764780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Influence of Physical Immobilization of dsDNA on Carbon Based Matrices of Electrochemical Sensors
Current Pharmaceutical Analysis Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Synthetic Thioamide, Benzimidazole, Quinolone and Derivatives with Carboxylic Acid and Ester Moieties: A Strategy in the Design of Antituberculosis Agents
Current Medicinal Chemistry Editorial Nutritional Therapy in Metabolic Syndrome
Current Vascular Pharmacology Will Sodium Intake Reduction Improve Cardiovascular Outcomes in the General Population? A Critical Review of Current Evidence
Current Hypertension Reviews Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design Viral Heart Disease and Acute Coronary Syndromes - Often or Rare Coexistence?
Current Pharmaceutical Design Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Biomarkers of Atrial Fibrillation in Hypertension
Current Medicinal Chemistry Molecular Determinants of Vascular Calcification: A Bench to Bedside View
Current Molecular Medicine Cardiac Cell Therapy and Bypass Surgery
Current Pharmaceutical Design New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Combinatorial Chemistry & High Throughput Screening Untargeted Metabolomics Provides Insight into the Mechanisms Underlying Resistant Hypertension
Current Medicinal Chemistry